

Valeant Pharmaceuticals Completes Bond Offering

Date: 02/08/11

Cahill represented the initial purchasers in a Rule 144A/Reg S Offering of \$650 million of 6.750% Senior Notes due 2021 by Valeant Pharmaceuticals International. Valeant intends to use the net proceeds from the offering of the Notes to finance acquisitions and for general corporate purposes.

Attorneys

- Noah B. Newitz
- Timothy B. Howell